19 October 2015
EMA/CHMP/684198/2015
Procedure Management and Committees Support Division

Committee for medicinal products for human use (CHMP)

Draft agenda for the meeting on 19-22 October 2015

Chair: Tomas Salmonson – Vice-Chair: Pierre Demolis

19 October 2015, 13:00 – 19:30, room 2A

20 October 2015, 08:30 – 19:30, room 2A

21 October 2015, 08:30 – 19:30, room 2A

22 October 2015, 08:30 – 13:00, room 2A

Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available.

Of note, this agenda is a working document primarily designed for CHMP members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

Table of contents

1. Introduction 8

1.1. Welcome and declarations of interest of members, alternates and experts 8

1.2. Adoption of agenda 8

1.3. Adoption of the minutes 8

2. Oral Explanations 8

2.1. Pre-authorisation procedure oral explanations 8

2.1.1. - insulin human - EMEA/H/C/003858 8

2.2. Re-examination procedure oral explanations 8

2.2.1. Heparesc - human heterologous liver cells - Orphan - ATMP - EMEA/H/C/003750 8

2.3. Post-authorisation procedure oral explanations 9

2.4. Referral procedure oral explanations 9

3. Initial applications 9

3.1. Initial applications; Opinions 9

3.1.1. - talimogene laherparepvec - ATMP - EMEA/H/C/002771 9

3.2. Initial applications; Day 180 list of outstanding issues 9

3.2.1. - atazanavir - EMEA/H/C/004048 9

3.2.2. - caspofungin - EMEA/H/C/004134 9

3.2.3. - lopinavir / ritonavir - EMEA/H/C/004025 9

3.2.4. - pemetrexed - EMEA/H/C/004109 10

3.2.5. - diphtheria, tetanus, pertussis (acellular, component), hepatitis b (rdna), poliomyelitis (inact.) and haemophilus type b conjugate vaccine (adsorbed) - EMEA/H/C/003982 10

3.2.6. - pitolisant - Orphan - EMEA/H/C/002616 10

3.2.7. - lesinurad - EMEA/H/C/003932 10

3.2.8. - mercaptamine - Orphan - EMEA/H/C/003769 11

3.3. Initial applications; Day 120 list of questions 11

3.3.1. - fluticasone propionate / salmeterol xinafoate -EMEA/H/C/002752 11

3.3.2. - fluticasone propionate / salmeterol xinafoate - EMEA/H/C/004267 11

3.3.3. - eftrenonacog alfa - Orphan - EMEA/H/C/004142 11

3.3.4. - aripiprazole - EMEA/H/C/004236 11

3.3.5. - osimertinib - EMEA/H/C/004124 11

3.3.6. - migalastat - Orphan - EMEA/H/C/004059 12

3.3.7. - drisapersen - Orphan - EMEA/H/C/003846 12

3.3.8. - obeticholic acid - Orphan - EMEA/H/C/004093 12

3.3.9. - pemetrexed - EMEA/H/C/003895 12

3.3.10. - zonisamide - EMEA/H/C/004127 12

3.4. Update on on-going initial applications for Centralised procedure 12

3.4.1. - Albutrepenonacog Alfa - Orphan - EMEA/H/C/003955 12
3.4.2. List of Questions adopted on 24.09.2015. - methotrexate - EMEA/H/C/003756 13
3.4.3. - enoxaparin sodium - EMEA/H/C/003795 13
3.4.4. - enoxaparin sodium - EMEA/H/C/004264 13
3.4.5. Vidaza - azacitidine - Orphan - EMEA/H/C/000978/II/0030 13
3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004 14
3.5.1. Heparesc - human heterologous liver cells - Orphan - ATMP - EMEA/H/C/003750 14
3.6. Initial applications in the decision-making phase 14
3.7. Withdrawals of initial marketing authorisation application 14

4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008 14

4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion 14
4.1.1. Emend - aprepitant - EMEA/H/C/000527/X/0049/G 14
4.1.2. Zostavax - shingles (herpes zoster) vaccine (live) - EMEA/H/C/000674/X/0085 15
4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues 15
4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question 15
4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008 15
4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008 15

5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008 15

5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information 15
5.1.1. Adcetris - brentuximab vedotin - Orphan - EMEA/H/C/002455/II/0025 15
5.1.2. Arzerra - ofatumumab - Orphan - EMEA/H/C/001131/II/0041 16
5.1.3. Avastin - bevacizumab - EMEA/H/C/000582/II/0086 16
5.1.4. Cosentyx - secukinumab - EMEA/H/C/003729/II/0001/G 16
5.1.5. Cosentyx - secukinumab - EMEA/H/C/003729/II/0002 17
5.1.6. Cubicin - daptomycin - EMEA/H/C/000637/II/0053/G 17
5.1.7. Edurant - rilpivirine - EMEA/H/C/002264/II/0017/G 17
5.1.8. Giotrif - afatinib - EMEA/H/C/002280/II/0012 18
5.1.9. Opdivo - nivolumab - EMEA/H/C/003985/II/0002 18
5.1.10. Opdivo - nivolumab - EMEA/H/C/003985/II/0003 18
5.1.11. Revlimid - lenalidomide - Orphan - EMEA/H/C/000717/II/0079 19

5.1.12. Revolade - eltrombopag / eltrombopag olamine - EMEA/H/C/001110/II/0023 19
5.1.13. Volibris - ambrisentan - Orphan - EMEA/H/C/000839/II/0041 19
5.1.14. Xalkori - crizotinib - EMEA/H/C/002489/II/0024 20
5.1.15. Zutectra - human hepatitis b immunoglobulin - EMEA/H/C/001089/II/0024 20
5.1.16. Zydelig - idelalisib - EMEA/H/C/003843/II/0011 20
5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008 21
5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008 21
6. Ancillary medicinal substances in medical devices 21
6.1. Ancillary medicinal substances in medical devices; Opinions/ Day 180 list of outstanding issues / Day 120 list of questions 21
6.2. Update of Ancillary medicinal substances in medical devices 21
7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use) 21
7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use) 21
8. Pre-submission issues 21
8.1. Pre-submission issue 21
8.1.1. - abaloparatide - H0004157 21
8.1.2. - bezlotoxumab - H0004136 21
8.1.3. - cabozantinib - H000416 22
8.1.4. - inotuzumab ozogamicin - H0004119 - Orphan 22
8.1.5. - Sofosbuvir / Velpatasvir - H0004210 22
8.1.6. - Venetoclax - Orphan - H0004106 22
9. Post-authorisation issues 23
9.1. Post-authorisation issues 23
9.1.1. Antiretroviral medicinal products: Ziagen - Abacavir – EMEA/H/C/000252/LEG 089.1; Kivexa -abacavir, lamivudine –EMEA/H/C/000581/LEG 045.1; Trizivir - abacavir, lamivudine, zidovudine - EMEA/H/C/000338/LEG 090.1; Reyataz - atazanavir– EMEA/H/C/000494/LEG 080.1; Prezista - darunavir - EMEA/H/C/000707/LEG 070.1; Stocrin - efavirenz – EMEA/H/C/000250/LEG 071.1, Sustiva - efavirenz – EMEA/H/C/000249/LEG 080.1; Atripla - efavirenz, emtricitabine, tenofovir disoproxil - EMEA/H/C/000797/LEG 040.1; Stribild - elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil - EMEA/H/C/002574/LEG 014.1; Emtriva - emtricitabine - EMEA/H/C/000533/LEG 049.2; Truvada - emtricitabine, tenofovir disoproxil –EMEA/H/C/000594/LEG 043.1; Eviplera - emtricitabine, rilpivirine, tenofovir disoproxil –EMEA/H/C/002312/LEG 031.1; Intelence - etravirine – EMEA/H/C/000900/LEG 048.1; Telzir -fosamprenavir - EMEA/H/C/000534/LEG 076.1; Crixivan - indinavir – EMEA/H/C/000128/LEG 039.1; Epivir - lamivudine - EMEA/H/C/000107/LEG 052.1, Lamivudine VIIV (Art 58) – lamivudine - EMEA/H/W/000673/LEG 007.1; Combivir - lamivudine, zidovudine - EMEA/H/C/000190/LEG 038.1; Aluvia - lopinavir, ritonavir - (Art 58) - EMEA/H/W/000764/LEG 031.1, Kaletra - lopinavir, ritonavir - EMEA/H/C/000368/LEG 118.1; Viramune - nevirapine - EMEA/H/C/000183/LEG 061.1; Edurant - rilpivirine –

EMEA/H/C/002264/LEG 026.1; Norvir - ritonavir - EMEA/H/C/000127/LEG 049.1; Invirase - saquinavir - EMEA/H/C/000113/LEG 065.1; Zerit - stavudine - EMEA/H/C/000110/LEG 060.1; Viread - tenofovir disoproxil - EMEA/H/C/000419/LEG 270.1; Aptivus - tipranavir - EMEA/H/C/000631/LEG 068.1 23

9.1.2. Cellcept - mycophenolate mofetil- EMEA/H/C/000082/II/0121 24

9.1.3. Tecfidera - Dimethyl Fumarate - EMEA/H/C/002601/WS0689/G; NAPs included in WS: Fumaderm, Fumaderm Intial 24

9.1.4. Fluenz Tetra - (A/California/7/2009 (H1n1)Pdm09-Like Strain (A/California/7/2009, Medi 228029),A/Texas/50/2012 (H3n2)-Like Strain (A/Texas/50/2012, Medi 237514),B/Brisbane/60/2008 (Victoria Lineage)-Like Strain (B/Brisbane/60/2008, Medi 228030),B/Massachusetts/2/2012 (Yamagata Lineage)-Like Strain (B/Massachusetts/2/2012, Medi 237751)) - EMEA/H/C/002617 24

9.1.5. Gilenya - fingolimod - EMEA/H/C/002202/II/0037 25

9.1.6. Viekirax - ombitasvir / paritaprevir / ritonavir - EMEA/H/C/003839/II/0006 25

9.1.7. Xarelto - Rivaroxaban - EMEA/H/C/000944 25

9.1.8. Xofigo - radium-223 - EMEA/H/C/002653 25

10. Referral procedures 26

10.1. Procedure for Centrally Authorised products under Article 20 Council Regulation (EC) No 726/2004 26

10.1.1. Inductos - Dibotermin alfa – EMEA/H/A-20/1422/C/0408/0082 26

10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004.. 26

10.3. Procedure under Articles 5(2) and 10 of the Regulation (EC) No 726/2004 26

10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC 26

10.4.1. Otipax 1% (11 mg/ml) ear drops, solution – lidocaine hydrochloride - EMEA/H/A-29/1426 26

10.4.2. Tobramycin VVB 300 mg/5 ml nebuliser solution – Tobramycin - EMEA/H/A-29/1428..... 27

10.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC.... 27

10.5.1. Durogesic transdermal patches – fentanyl - EMEA/H/A-30/1413 27

10.5.2. Etopophos and associated names– etoposide - EMEA/H/A-30/1417..... 27

10.5.3. Vepesid and associated names - etoposide - EMEA/H/A-30/1425 28

10.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC 28

10.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC..... 28

10.8. Procedure under Article 107(2) of Directive 2001/83/EC 28

10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) (EC) No 1084/2003 28

10.10. Procedure under Article 29 Regulation (EC) 1901/2006..... 28

10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) No 1234/2008)..... 28

10.11.1. Levonelle 1500mcg tablets – Levonorgestrel - EMEA/H/A-13/1427 28

11. Pharmacovigilance issue 29

11.1. Early Notification System 29

12. Inspections 29

12.1. GMP inspections 29

12.2. GCP inspections 29

12.3. Pharmacovigilance inspections 29

12.4. GLP inspections 29

13. Innovation Task Force 30

13.1. Minutes of Innovation Task Force 30

13.2. Innovation Task Force briefing meetings 30

13.2.1. ITF Briefing Meeting 30

13.2.2. ITF Briefing Meeting 30

13.2.3. ITF Briefing Meeting 30

13.3. Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004 30

13.4. Nanomedicines activities 30

14. Organisational, regulatory and methodological matters 30

14.1. Mandate and organisation of the CHMP 30

14.1.1. Discussion of CHMP co-opted member expertise 30

14.1.2. Updated Assessment Report templates 31

14.1.3. Draft Scientific Guideline on Post-authorisation efficacy studies (PAES) 31

14.1.4. Enhanced early dialogue to foster development and facilitate accelerated assessment (PRIME) 31

14.1.5. Strategic Review and Learning Meetings 31

14.1.6. Strategic review of the Article 58 procedure 31

14.1.7. Concept paper on guideline on pregnancy and breastfeeding (GVP) 31

14.2. Coordination with EMA Scientific Committees 32

14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC) 32

14.2.2. Committee for Advanced Therapies (CAT) 32

14.2.3. Committee for Herbal Medicinal Products (HMPC) 32

14.2.4. Paediatric Committee (PDCO) 32

14.2.5. Committee for Orphan Medicinal Products (COMP) 32

14.2.6. CMDh 32

14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups 33

14.3.1. Scientific Advice Working Party (SAWP) 33

14.3.2. Safety Working Party (SWP) 33

14.3.3. Quality Working Party (QWP) 33

14.3.4. Biologics Working Party (BWP) 34
14.3.5. Blood Products Working Party (BPWP) 34
14.3.6. Cardiovascular Working Party 34
14.3.7. Central Nervous System Working Party (CNSWP) 34
14.3.8. Pharmacokinetics Working Party (PKWP) 34
14.3.9. Excipients Drafting Group 34
14.3.10. Biostatistics Working Party (BSWP) 35
14.3.11. Asthma Guideline Drafting Group 35
14.3.12. CHMP-GCP inspectors working group 35
14.3.13. Joint CVMP/CHMP ad-hoc expert group on the application of the 3Rs (replacement, reduction and refinement) in the regulatory testing of medicinal products (JEG 3Rs) 35
14.4. Cooperation within the EU regulatory network 35
14.4.1. EPAA Annual conference in Brussels (EP), 1st December 2015, ... 35
14.5. Cooperation with International Regulators 36
14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee 36
14.6.1. International Society for Stem Cell Research 36
14.7. CHMP work plan 36
14.8. Planning and reporting 36
14.9. Others 36

15. Any other business 36

15.1. AOB topic 36

16. Explanatory notes 37

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CHMP plenary session to be held 19-22 October 2015. See October 2015 CHMP minutes (to be published post November 2015 CHMP meeting).

1.2. Adoption of agenda

CHMP agenda for 19-22 October 2015

1.3. Adoption of the minutes

CHMP minutes for 21-24 September 2015.

2. Oral Explanations

2.1. Pre-authorisation procedure oral explanations

2.1.1. - insulin human - EMEA/H/C/003858

treatment of diabetes

Scope: Oral explanation

Action: Oral explanation to be held on Tuesday 20 October 2015 at 9.00.

List of Outstanding Issues adopted on 25.06.2015. List of Questions adopted on 23.10.2014.

BWP Report

2.2. Re-examination procedure oral explanations

2.2.1. Heparesc - human heterologous liver cells - Orphan - ATMP - EMEA/H/C/003750

Cytonet GmbH&Co KG; treatment of urea cycle disorders (UCD)

Scope: Oral explanation and opinion

Action: Oral explanation to be held on Tuesday 20 October 2015 at 14.00.

Report from ad-hoc expert group held on 6 October 2015.

See also 3.5.1

2.3. Post-authorisation procedure oral explanations

2.4. Referral procedure oral explanations

3. Initial applications

3.1. Initial applications; Opinions

3.1.1. - talimogene laherparepvec - ATMP - EMEA/H/C/002771

treatment of adults with melanoma that is regionally or distantly metastatic

Scope: Opinion and Possible oral explanation (to be confirmed)

Action: For adoption

List of Outstanding Issues adopted on 24.09.2015 and 25.06.2015. List of Questions adopted on 22.01.2015.

3.2. Initial applications; Day 180 list of outstanding issues

3.2.1. - atazanavir - EMEA/H/C/004048

treatment of HIV-1.

Scope: Day 180 list of outstanding issue

Action: For adoption

List of Questions adopted on 21.05.2015.

3.2.2. - caspofungin - EMEA/H/C/004134

treatment of invasive candidiasis and invasive aspergillosis

Scope: Day 180 list of outstanding issue

Action: For adoption

List of Questions adopted on 23.07.2015.

3.2.3. - lopinavir / ritonavir - EMEA/H/C/004025

treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children above the age of 2 years.

Scope: Day 180 list of outstanding issue

Action: For adoption

List of Questions adopted on 21.05.2015.

3.2.4. - pemetrexed - EMEA/H/C/004109

treatment of malignant pleural mesothelioma and non-small cell lung cancer

Scope: 2nd Day 180 list of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 24.09.2015. List of Questions adopted on 25.06.2015.

3.2.5. - diphtheria, tetanus, pertussis (acellular, component), hepatitis b (rdna), poliomyelitis (inact.) and haemophilus type b conjugate vaccine (adsorbed) - EMEA/H/C/003982

vaccination against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae typeb (Hib)

Scope: Day 180 list of outstanding issue

Action: For adoption

List of Questions adopted on 21.05.2015.

BWP Report

3.2.6. - pitolisant - Orphan - EMEA/H/C/002616

BIOPROJET PHARMA; treatment of narcolepsy

Scope: 2nd Day 180 list of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 21.05.2015. List of Questions adopted on 25.09.2014.

3.2.7. - lesinurad - EMEA/H/C/003932

treatment of hyperuricaemia

Scope: Day 180 list of outstanding issue

Action: For adoption

List of Questions adopted on 21.05.2015.

3.2.8. - mercaptamine - Orphan - EMEA/H/C/003769

Orphan Europe S.A.R.L.; treatment of cystinosis

Scope: 2nd Day 180 list of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 24.09.2015 and 25.06.2015. List of Questions adopted on 22.01.2015.

3.3. Initial applications; Day 120 list of questions

3.3.1. - fluticasone propionate / salmeterol xinafoate -EMEA/H/C/002752

treatment of asthma and COPD

Scope: Day 120 list of questions

Action: For adoption

3.3.2. - fluticasone propionate / salmeterol xinafoate - EMEA/H/C/004267

treatment of asthma and COPD

Scope: Day 120 list of questions

Action: For adoption

3.3.3. - eftrenonacog alfa - Orphan - EMEA/H/C/004142

Biogen Idec Ltd; treatment and prophylaxis of bleeding in patients with haemophilia B

Scope: Day 120 list of questions

Action: For adoption

BWP Report

3.3.4. - aripiprazole - EMEA/H/C/004236

treatment of schizophrenia, treatment and prevention of bipolar disorder (manic episodes)

Scope: Day 120 list of questions

Action: For adoption

3.3.5. - osimertinib - EMEA/H/C/004124

non-small-cell lung cancer (NSCLC)

Scope: Day 120 list of questions

Action: For adoption

3.3.6. - migalastat - Orphan - EMEA/H/C/004059

Amicus Therapeutics UK Ltd; Treatment of patients with Fabry disease

Scope: Day 120 list of questions

Action: For adoption

3.3.7. - drisapersen - Orphan - EMEA/H/C/003846

BioMarin International Limited; treatment of Duchenne muscular dystrophy (DMD)

Scope: Day 120 list of questions

Action: For adoption

3.3.8. - obeticholic acid - Orphan - EMEA/H/C/004093

Intercept Italia s.r.l; treatment of primary biliary cirrhosis

Scope: Day 120 list of questions

Action: For adoption

3.3.9. - pemetrexed - EMEA/H/C/003895

treatment of malignant pleural mesothelioma and non-small cell lung cancer

Scope: Day 120 list of questions

Action: For adoption

3.3.10. - zonisamide - EMEA/H/C/004127

treatment of epilepsy

Scope: Day 120 list of questions

Action: For adoption

3.4. Update on on-going initial applications for Centralised procedure

3.4.1. - Albutrepenonacog Alfa - Orphan - EMEA/H/C/003955

CSL Behring GmbH, prophylaxis and treatment of bleeding in all patients with haemophilia B, treatment of bleeding in all patients with haemophilia B

Scope: Pre-authorisation testing request

Action: For adoption

3.4.2. List of Questions adopted on 24.09.2015. - methotrexate - EMEA/H/C/003756

treatment of rheumatological and dermatological diseases

Scope: Letter from the applicant requesting extension of clock stop to respond to Day 120 list of questions adopted on 23 July 2015.

Action: For discussion

3.4.3. - enoxaparin sodium - EMEA/H/C/003795

prophylaxis of thromboembolic disorders of venous origin

Scope: Revised timetable

Action: For adoption

3.4.4. - enoxaparin sodium - EMEA/H/C/004264

prophylaxis of thromboembolic disorders of venous origin

Scope: Revised timetable

Action: For adoption

3.4.5. Vidaza - azacitidine - Orphan - EMEA/H/C/000978/II/0030

Celgene Europe Limited

Rapporteur: Pieter de Graeff, Co-Rapporteur: Arantxa Sancho-Lopez, PRAC Rapporteur: Sabine Straus

Scope: AML and cut-off age: Vidaza-Dacogen“Extension of Indication to add treatment of adult patients aged 65 years or older who are not eligible for HSCT with AML with >30% marrow blasts according to the WHO classification, based on the pivotal phase III study AZA- AML-001. As a consequence, sections 4.1, 4.4, 4.8 and 5.1 of the SmPC have been updated and the Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to implement minor editorial changes in the SmPC and Package Leaflet. A revised RMP version 10.0 was provided as part of the application. The application includes a request for an additional year of market protection for a new indication in accordance with Article 10(1) of Directive 2001/83/EC.”, Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For discussion

Opinion adopted on 24.09.2015

3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004

3.5.1. Heparesc - human heterologous liver cells - Orphan - ATMP - EMEA/H/C/003750

Cytonet GmbH&Co KG; treatment of urea cycle disorders (UCD)

Scope: Oral explanation and opinion

Action: Oral explanation to be held on Tuesday 20 October 2015 at 14.00.

Report from ad-hoc expert group held on 6 October 2015.

3.6. Initial applications in the decision-making phase

3.7. Withdrawals of initial marketing authorisation application

4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion

4.1.1. Emend - aprepitant - EMEA/H/C/000527/X/0049/G

Merck Sharp & Dohme Limited; prevention of nausea and vomiting in cancer chemotherapy

Rapporteur: Filip Josephson, Co-Rapporteur: Pieter de Graeff, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "The MAH has submitted a type II variation classified as C.I.6 to extend the indication for chemotherapy-induced nausea and vomiting (CINV) in adults to paediatric patients (12 to 17years) for the 80mg and 125mg hard capsules. SmPC section 4.2 and 5.3 of the 165mg hard capsule label, which is consequential to the outcome of this grouped procedure, will be updated under the scope of type II variation classified as C.I.6.
In addition to this, an application for an addition of a new pharmaceutical form (powder for oral suspension) has been submitted for 125mg strength as part of this grouping.
The MAH has also submitted a type II variation classified as C.I.4 to reflect the paediatric results for prevention of post-operative nausea and vomiting (PONV) in the clinical sections of 40mg hard capsules label, thus updating sections 5.1 and 5.2 of the SmPC.
The Package Leaflet has been proposed to be updated accordingly."

Action: For adoption

List of Outstanding Issues adopted on 24.09.2015. List of Questions adopted on 23.04.2015.

4.1.2. Zostavax - shingles (herpes zoster) vaccine (live) - EMEA/H/C/000674/X/0085

Sanofi Pasteur MSD SNC

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: “Addition of the route of administration "intramuscular" for all presentations.”

Action: For adoption

List of Questions adopted on 21.05.2015.

4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues

4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question

4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008

4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008

5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information

5.1.1. Adcetris - brentuximab vedotin - Orphan - EMEA/H/C/002455/II/0025

Takeda Pharma A/S

Rapporteur: Pieter de Graeff, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Sabine Straus

Scope: “Extension of Indication to include new indication for Adcetris (ADCETRIS is indicated for the treatment of adult patients at increased risk of relapse or progression following ASCT”). as a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance.”

Action: For adoption

Request for Supplementary Information adopted on 25.06.2015.

5.1.2. Arzerra - ofatumumab - Orphan - EMEA/H/C/001131/II/0041

Novartis Europharm Ltd

Rapporteur: Sinan B. Sarac, Co-Rapporteur: Karsten Bruins Slot, PRAC Rapporteur: Doris Stenver

Scope: “Extension of Indication to include maintenance therapy in Chronic Lymphocytic Leukemia (CLL).
As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance.
In accordance with the new QRD template version 9.1, the MAH is also taking the opportunity of this procedure to update the Annex II and combine the 2 SmPCs for the 100mg an 1,000mg vials.”

Action: For adoption

5.1.3. Avastin - bevacizumab - EMEA/H/C/000582/II/0086

Roche Registration Ltd

Rapporteur: Sinan B. Sarac, Co-Rapporteur: Karsten Bruins Slot, PRAC Rapporteur: Doris Stenver

Scope: “Extension of indication to extend the use of Avastin in combination with erlotinib for the first line treatment of patients with unresectable advanced, metastatic or recurrent non-squamous NSCLC with EGFR activating mutations. As a consequence sections 4.1, 4.2, 4.5, 4.8 and 5.1 of the SmPC are proposed to be updated. The Package Leaflet and RMP are updated in accordance.”

Action: For adoption

5.1.4. Cosentyx - secukinumab - EMEA/H/C/003729/II/0001/G

Novartis Europharm Ltd

Rapporteur: Tuomo Lapveteläinen, Co-Rapporteur: Kristina Dunder, PRAC Rapporteur: Dolores Montero Corominas

Scope: “Extension of Indication to include new indication for Cosentyx “treatment of active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate as monotherapy or in combination with methotrexate (MTX)”.
As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, and 5.2 of the SmPC are updated in order to update the safety and efficacy information. The Package Leaflet is updated in

accordance. Furthermore, minor editorial changes have been introduced throughout the PI and updated RMP has been also submitted."

Action: For adoption

Request for Supplementary Information adopted on 25.06.2015.

5.1.5. Cosentyx - secukinumab - EMEA/H/C/003729/II/0002

Novartis Europharm Ltd

Rapporteur: Tuomo Lapveteläinen, Co-Rapporteur: Kristina Dunder, PRAC Rapporteur: Dolores Montero Corominas

Scope: "Extension of indication to add new indication for Cosentyx 'treatment of severe active ankylosing spondylitis in adults who have responded inadequately to conventional therapy'. Consequently SmPC sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, and 5.2 have been revised to include new efficacy and safety information. The Package Leaflet and RMP have been updated accordingly.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 25.06.2015.

5.1.6. Cubicin - daptomycin - EMEA/H/C/000637/II/0053/G

Novartis Europharm Ltd

Rapporteur: Greg Markey, PRAC Rapporteur: Julie Williams

Scope: "Extension of Indication to extend the age range for the indication "complicated skin and soft-tissue infections" (cSSTI) to include paediatric patients from 1 to 17 years of age for Cubicin. As a consequence sections 4.1, 4.2, 4.4, 5.2 and 6.2 of the SmPC are being updated. The Package Leaflet is updated accordingly. Moreover, the updated RMP version 9.0 has been submitted."

Action: For adoption

5.1.7. Edurant - rilpivirine - EMEA/H/C/002264/II/0017/G

Janssen-Cilag International N.V.

Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Sabine Straus

Scope: "Extension of Indication to include treatment of ARV treatment-naïve paediatric patients aged 12 to <18 years of age based on the results of the 48-week data of study TMC278-TiDP38-C213 (PAINT), undertaken to evaluate the pharmacokinetics, safety/ tolerability, and efficacy of RPV 25 mg qd in combination with an investigator-selected background regimen containing 2
nucleoside (nucleotide) reverse transcriptase inhibitors (NRTIs) in this adolescent population.
As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC have been updated and the Package Leaflet has been updated accordingly.
A revised RMP version 6.0 was included as part of this application."

Action: For adoption

Request for Supplementary Information adopted on 25.06.2015.

5.1.8. Giotrif - afatinib - EMEA/H/C/002280/II/0012

Boehringer Ingelheim International GmbH

Rapporteur: Filip Josephson, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension of Indication to include patients with locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy for Giotrif. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet and RMP are updated in accordance. Furthermore, minor editorial changes have been introduced throughout the PI.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

5.1.9. Opdivo - nivolumab - EMEA/H/C/003985/II/0002

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Arantxa Sancho-Lopez, Co-Rapporteur: Pieter de Graeff, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of Indication to include treatment as monotherapy of locally advanced or metastatic non-squamous NSCLC after prior chemotherapy in adults based on study CA209057. As a consequence, sections 4.1, 4.4, 4.8 and 5.1 of the SmPC have been updated and the Package Leaflet has been updated accordingly. Further, SmPC section 4.8 has been revised with updated combined clinical trial exposure numbers to reflect inclusion of studies in non-squamous NSCLC and in nivolumab in combination with ipilimumab in advanced melanoma. In addition, the MAH took the opportunity to align the annexes with the latest QRD template version 9.1 and to implement minor editorial changes. A revised RMP version 3.0 was provided as part of the application."

Action: For adoption

5.1.10. Opdivo - nivolumab - EMEA/H/C/003985/II/0003

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Arantxa Sancho-Lopez, Co-Rapporteur: Pieter de Graeff, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of Indication to include treatment in combination with ipilimumab of advanced (unresectable or metastatic) melanoma in adults based on interim data from study CA209067 and the final CSR of study CA209069. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC have been updated and the Package Leaflet has been revised accordingly. In addition, the MAH took the opportunity to implement minor editorial changes in the SmPC, Annex II and Package Leaflet. An updated RMP version 3.0 was provided as part of the application as well as a paediatric non-clinical biomarker

study provided to fulfil paediatric requirements."

Action: For adoption

5.1.11. Revlimid - lenalidomide - Orphan - EMEA/H/C/000717/II/0079

Celgene Europe Limited

Rapporteur: Pierre Demolis, Co-Rapporteur: Filip Josephson, PRAC Rapporteur: Arnaud Batz

Scope: "Extension of Indication to add treatment of adult patients with relapsed and/ or refractory mantle cell lymphoma (MCL). As a consequence, SmPC sections 4.1, 4.2, 4.5, 4.8, 5.1 and 5.2 have been updated and the Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to make minor editorial changes in the SmPC and Package Leaflet. A revised version of the RMP (version 25.0) was provided as part of this application."

Action: For adoption

Request for Supplementary Information adopted on 23.07.2015, 26.03.2015.

5.1.12. Revolade - eltrombopag / eltrombopag olamine - EMEA/H/C/001110/II/0023

Novartis Europharm Ltd

Rapporteur: Arantxa Sancho-Lopez, Co-Rapporteur: Greg Markey, Scope: "Extension of Indication to extend the use of Revolade to non-splenectomized patients.
As a consequence, section 4.1 of the SmPC is updated. The Package Leaflet is updated in accordance."

Action: For adoption

Request for Supplementary Information adopted on 25.06.2015.

5.1.13. Volibris - ambrisentan - Orphan - EMEA/H/C/000839/II/0041

Glaxo Group Ltd

Rapporteur: Concepcion Prieto Yerro, Co-Rapporteur: Radka Montoniová, PRAC Rapporteur: Dolores Montero Corominas

Scope: "Update of sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to include an expanded therapeutic indication for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group 1)
In addition, the MAH took the opportunity to update Annex II to reflect a change in the PSUR cycle.
The Package leaflet is proposed to be updated accordingly."

Action: For adoption

Request for Supplementary Information adopted on 24.09.2015, 23.07.2015, 26.03.2015.

5.1.14. Xalkori - crizotinib - EMEA/H/C/002489/II/0024

Pfizer Limited

Rapporteur: Pierre Demolis, Co-Rapporteur: Daniela Melchiorri, PRAC Rapporteur: Corinne Fechant

Scope: "Extension of indication to the first-line treatment of anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung carcinoma (NSCLC). This variation is based on results taken from Study A8081014
As a consequence; sections 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC have been amended. The Package Leaflet is updated in accordance."

Action: For adoption

Request for Supplementary Information adopted on 23.07.2015, 26.03.2015.

5.1.15. Zutectra - human hepatitis b immunoglobulin - EMEA/H/C/001089/II/0024

Biotest Pharma GmbH

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Robert James Hemmings, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of Indication to Prevention of hepatitis B virus (HBV) re-infection in HBsAg and HBV-DNA negative patients at least one week – instead of the approved at least 6 months - after liver transplantation for hepatitis B induced liver failure.
As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated accordingly.
An updated RMP has been provided."

Action: For adoption

Request for Supplementary Information adopted on 23.07.2015.

5.1.16. Zydelig - idelalisib - EMEA/H/C/003843/II/0011

Gilead Sciences International Ltd

Rapporteur: Kristina Dunder, PRAC Rapporteur: Rafe Suvarna

Scope: "Extension of Indication to include new indication for Zydelig to include the combination of idelalisib with ofatumumab. As a consequence, sections 4.1, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance.
In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives for United Kingdom and Ireland in the Package Leaflet."

Action: For adoption

5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

6. Ancillary medicinal substances in medical devices

6.1. Ancillary medicinal substances in medical devices; Opinions/ Day 180 list of outstanding issues / Day 120 list of questions

6.2. Update of Ancillary medicinal substances in medical devices

7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

8. Pre-submission issues

8.1. Pre-submission issue

8.1.1. - abaloparatide - H0004157

treatment of osteoporosis in postmenopausal women

Scope: Request for an Accelerated Assessment

Action: For adoption

Letter from the company requesting an accelerated assessment

Rapporteurs' accelerated assessment briefing note

8.1.2. - bezlotoxumab - H0004136

prevention of Clostridium difficile infection (CDI) recurrence in adult patients receiving antibiotic therapy for CDI

Scope: Request for an Accelerated Assessment

Action: For adoption

Letter from the company dated 21 September 2015 requesting an accelerated assessment

Rapporteurs' accelerated assessment briefing note

8.1.3. - cabozantinib - H000416

treatment of renal cell carcinoma

Scope: Request for an Accelerated Assessment

Action: For adoption

Letter from the company dated 27 August 2015 requesting an accelerated assessment

Rapporteurs' accelerated assessment briefing note.

8.1.4. - inotuzumab ozogamicin - H0004119 - Orphan

Pfizer Limited, treatment of relapsed or refractory b cell Acute Lymphoblastic Leukaemia

Scope: Request for an Accelerated Assessment

Action: For adoption

Letter from the company requesting an accelerated assessment

Rapporteurs' accelerated assessment briefing note.

8.1.5. - Sofosbuvir / Velpatasvir - H0004210

treatment of genotype 1-6 chronic hepatitis C virus (HCV) infection in adults

Scope: Request for an Accelerated Assessment

Action: For adoption

Letter from the company requesting an accelerated assessment

Rapporteurs' accelerated assessment briefing note

8.1.6. - Venetoclax - Orphan - H0004106

AbbVie Ltd., treatment of adult patients with chronic lymphocytic leukaemia in the presence of 17p deletion

Scope: Request for an Accelerated Assessment

Action: For adoption

Letter from the company dated 5 October 2015 requesting an accelerated assessment

Rapporteurs' accelerated assessment briefing note

9. Post-authorisation issues

9.1. Post-authorisation issues

9.1.1. Antiretroviral medicinal products: Ziagen - Abacavir – EMEA/H/C/000252/LEG 089.1; Kivexa -abacavir, lamivudine – EMEA/H/C/000581/LEG 045.1; Trizivir - abacavir, lamivudine, zidovudine - EMEA/H/C/000338/LEG 090.1; Reyataz - atazanavir– EMEA/H/C/000494/LEG 080.1; Prezista - darunavir - EMEA/H/C/000707/LEG 070.1; Stocrin - efavirenz – EMEA/H/C/000250/LEG 071.1, Sustiva - efavirenz – EMEA/H/C/000249/LEG 080.1; Atripla - efavirenz, emtricitabine, tenofovir disoproxil - EMEA/H/C/000797/LEG 040.1; Stribild - elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil - EMEA/H/C/002574/LEG 014.1; Emtriva - emtricitabine - EMEA/H/C/000533/LEG 049.2; Truvada - emtricitabine, tenofovir disoproxil – EMEA/H/C/000594/LEG 043.1; Eviplera - emtricitabine, rilpivirine, tenofovir disoproxil –EMEA/H/C/002312/LEG 031.1; Intelence - etravirine – EMEA/H/C/000900/LEG 048.1; Telzir -fosamprenavir - EMEA/H/C/000534/LEG 076.1; Crixivan - indinavir –EMEA/H/C/000128/LEG 039.1; Epivir - lamivudine - EMEA/H/C/000107/LEG 052.1, Lamivudine VIIV (Art 58) – lamivudine - EMEA/H/W/000673/LEG 007.1; Combivir - lamivudine, zidovudine - EMEA/H/C/000190/LEG 038.1; Aluvia - lopinavir, ritonavir - (Art 58) - EMEA/H/W/000764/LEG 031.1, Kaletra - lopinavir, ritonavir - EMEA/H/C/000368/LEG 118.1; Viramune - nevirapine - EMEA/H/C/000183/LEG 061.1; Edurant - rilpivirine – EMEA/H/C/002264/LEG 026.1; Norvir - ritonavir - EMEA/H/C/000127/LEG 049.1; Invirase - saquinavir - EMEA/H/C/000113/LEG 065.1; Zerit - stavudine - EMEA/H/C/000110/LEG 060.1; Viread - tenofovir disoproxil - EMEA/H/C/000419/LEG 270.1; Aptivus - tipranavir - EMEA/H/C/000631/LEG 068.1

Applicants: AbbVie Ltd (Kaletra, Norvir), Boehringer Ingelheim International GmbH (Aptivus, Viramune), Bristol-Myers Squibb Pharma EEIG (Reyataz, Sustiva, Zerit), Bristol-Myers Squibb and Gilead Sciences Ltd.(Atripla), Gilead Sciences International Ltd.(Emtriva, Eviplera, Stribild, Truvada, Tybost, Viread), Janssen-Cilag International N.V.(Edurant, Intelence, Prezista), Merck Sharp & Dohme Ltd (Crixivan, Isentress, Stocrin), Roche Registration Ltd. (Invirase), ViiV Healthcare UK Limited (Celsentri, Combivir, Epivir, Lamivudine Viiv, Kivexa, Telzir, Trizivir, Ziagen)

PRAC Rapporteur (lead): Qun-Ying Yue; PRAC Co-Rapporteur: Isabelle Robine; Julie Williams

Scope: Class labelling revision on lipodystrophy and lactic acidosis, Communication

Action: For adoption

9.1.2. Cellcept - mycophenolate mofetil- EMEA/H/C/000082/II/0121

Roche Registration Ltd, prophylaxis of acute transplant rejection

Rapporteur: Rafe Suvarna,

Scope: Request for Supplementary information
Update of sections 4.4 and 4.6 of the SmPC in order to add a warning for pregnant women and update the safety information related to pregnancy. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the PI in line with the latest QRD template version.
The requested variation proposed amendments to the Summary of Product Characteristics and Package Leaflet."

Action: For adoption

Request for Supplementary Information adopted on 24.09.2015, 25.06.2015, 26.03.2015.

9.1.3. Tecfidera - Dimethyl Fumarate - EMEA/H/C/002601/WS0689/G; NAPs included in WS: Fumaderm, Fumaderm Intial

Biogen Idec Ltd, Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber

Scope: Opinion

Action: For adoption

Update of sections 4.4 of the SmPC in order to add a recommendation to consider interruption of treatment in patients with low lymphocyte counts (<0.5 x 109/L) persisting for more than six months and to monitor lymphocyte counts until recovery. Update of section 4.8 of the SmPC with information on observed low lymphocyte counts in clinical studies with Tecfidera and PML (Progressive multifocal leukoencephalopathy) occurrence in the setting of severe and prolonged lymphopenia. Furthermore, the due dates of two commitments as part of the RMP have been revised."

Request for Supplementary information adopted on 26.02.2015, 23.04.2015, 23.07.2015, 24.09.2015. SAG Neurology held on 11 June 2015. Oral explanation held on 22.09.2015.

9.1.4. Fluenz Tetra - (A/California/7/2009 (H1n1)Pdm09-Like Strain (A/California/7/2009, Medi 228029),A/Texas/50/2012 (H3n2)-Like Strain (A/Texas/50/2012, Medi 237514),B/Brisbane/60/2008 (Victoria Lineage)-Like Strain (B/Brisbane/60/2008, Medi 228030),B/Massachusetts/2/2012 (Yamagata Lineage)-Like Strain (B/Massachusetts/2/2012, Medi 237751)) - EMEA/H/C/002617

MedImmune LLC, Prophylaxis of influenza in individuals 24 months to less than 18 years

Rapporteur: Daniel Brasseur, Co-Rapporteur: Karsten Bruins Slot,

Action: For discussion

9.1.5. Gilenya - fingolimod - EMEA/H/C/002202/II/0037

Novartis Europharm Ltd, treatment of multiple sclerosis

Rapporteur: Pierre Demolis, PRAC Rapporteur: Isabelle Robine,

Scope: Opinion or Request for supplementary information
"Update of sections 4.4 and 4.8 of the SmPC in order to update the safety information to include additional warning and guidance on PML. The Package Leaflet is updated accordingly."

Action: For adoption

9.1.6. Viekirax - ombitasvir / paritaprevir / ritonavir - EMEA/H/C/003839/II/0006

AbbVie Ltd.,

Rapporteur: Filip Josephson,

"Update of sections 4.5 and 5.2 of the SmPC to indicate that paritaprevir is eliminated predominantly via biliary excretion as recommended by the CHMP in the Post Authorisation Measure MEA 002."

Action: For adoption

9.1.7. Xarelto - Rivaroxaban - EMEA/H/C/000944

Bayer Pharma AG, prevention of venous thromboembolism (VTE) ,prevention of venous thromboembolism (VTE), prevention of stroke and systemic embolism

Rapporteur: Kristina Dunder, Co-Rapporteur: Martina Weise,

Scope:

Action: For discussion

9.1.8. Xofigo - radium-223 - EMEA/H/C/002653

Bayer Pharma AG, treatment of castration-resistant prostate cancer

Rapporteur: Harald Enzmann, Co-Rapporteur: Daniela Melchiorri,

Follow up on update of the Product Information to correct the radioactivity of the drug product solution contained in the vial from 1000 kBq/mL to 1100 kBq/mL at reference date and of the patient dose from 50 kBq/kg body weight to 55 kBq/kg body weight as a result of the change of the National Institute of Standards and Technology primary

reference standard used to quantify the radioactivity of radium-223 (variation EMEA/H/C/2653/II/11)

Scope: Xofigo second DHPC on NIST implementation (follow up from variation EMEA/H/C/2653/II/11 and from first DHPC on NIST implementation adopted by CHMP in March 2015)

Action: For adoption

10. Referral procedures

10.1. Procedure for Centrally Authorised products under Article 20 Council Regulation (EC) No 726/2004

10.1.1. Inductos - Dibotermin alfa – EMEA/H/A-20/1422/C/0408/0082

Medtronic BioPharma B.V., treatment of anterior lumbar spine fusion and tibia fracturesRapporteur: Pieter de Graeff, Co-Rapporteur: Outi Mäki-Ikola,

Scope: Opinion
Non-GMP compliance of a manufacturing site

Action: For adoption

10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004

10.3. Procedure under Articles 5(2) and 10 of the Regulation (EC) No 726/2004

10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC

10.4.1. Otipax 1% (11 mg/ml) ear drops, solution – lidocaine hydrochloride - EMEA/H/A-29/1426

Biocodex Benelux SA/NV

RMS: BE, CMS: AT, CY, DE, DK, EL, ES, FI, IT, NO, PL, PT, SE, Mutual recognition procedure number: BE/H/0213/001/MR

Scope: List of questions and timetable, appointment of (Co)Rapporteur

Disagreements regarding efficacy and the evidence of well-established use.

Action: For adoption

Letter from the Federal agency for medicines and health products in Belgium dated 2 October 2015 notifying of an official referral under Article 29(4) and its grounds.

10.4.2. Tobramycin VVB 300 mg/5 ml nebuliser solution – Tobramycin - EMEA/H/A-29/1428

UAB VVB

RMS: LT, CMS: BG, EE, HU, LV, PL, RO, Decentralised Procedure Number: LT/H/0112/001/DC

Scope: List of questions and timetable, appointment of (Co)Rapporteur

Action: For adoption

Letter from the State Medicines Control Agency in Lithuania dated 09 October 2015 and updated letter dated 14 October 2015 notifying of an official referral under Article 29(4) and its grounds.

10.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC

10.5.1. Durogesic transdermal patches – fentanyl - EMEA/H/A-30/1413

MAH: Janssen-Cilag group of companies and associated companies

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Martina Weise,

Scope: Revised timetable

Letter from the MAH dated 7 October 2015 requesting a 2-month extension of timeframe to submit responses to the List of Questions adopted on 24 September 2015.

Action: For information

Start of procedure (CHMP): September 2015 CHMP

Submission of responses: 01.12.2015

Re-start of the procedure: 21.12.2015

Rapporteur/co-rapporteur assessment report(s) circulated to CHMP: 13.01.2016

Comments: 18.01.2016

Updated rapporteur/co-rapporteur assessment report(s) circulated to CHMP: 21.01.2016

List of outstanding issues or CHMP opinion: January 2016 CHMP

10.5.2. Etopophos and associated names– etoposide - EMEA/H/A-30/1417

MAH: Bristol-Myers Squibb group of companies and associated companies

Rapporteur: Greg Markey, Co-Rapporteur: Pieter de Graeff

Scope: List of questions and timetable

Harmonisation exercise for Etopophos and associated names

Letter from the European Commission dated 14 October 2015 notifying of an official referral under Article 30.

Action: For adoption

Note: The Rapporteurs were appointed by CHMP in October 2014

10.5.3. Vepesid and associated names - etoposide - EMEA/H/A-30/1425

MAH: Bristol-Myers Squibb group of companies and associated companies

Rapporteur: Greg Markey, Co-Rapporteur: Pieter de Graeff

Scope: List of questions and timetable

Harmonisation exercise for Etopophos and associated names

Letter from the European Commission dated 14 October 2015 notifying of an official referral under Article 30.

Action: For adoption

Note: The Rapporteurs were appointed by CHMP in October 2014

10.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC

10.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC

10.8. Procedure under Article 107(2) of Directive 2001/83/EC

10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) (EC) No 1084/2003

10.10. Procedure under Article 29 Regulation (EC) 1901/2006

10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) No 1234/2008)

10.11.1. Levonelle 1500mcg tablets – Levonorgestrel - EMEA/H/A-13/1427

MAH: Medimpex UK Limited,

RMS: UK, CMS: AT, BE, CZ, DE, EL, FR, IE, IS, IT, LT, LU, NL, NO, PL, PT, SE, Mutual recognition procedure: UK/H/0803/001/II/022

Scope: List of questions and timetable, appointment of (Co)Rapporteur

Action: For adoption

Letter from the MHRA in UK dated 5 October 2015 notifying of an official referral under Article 13(1) and its grounds.

11. Pharmacovigilance issue

11.1. Early Notification System

October 2015 Early Notification System on Envisaged CHMP Recommendations for Regulatory Action (based on Identified Safety Concerns) Accompanied by Communication to the General Summary of recommendations and advice of PRAC meeting held on 05-08 October 2015.

Action: For information

12. Inspections

12.1. GMP inspections

Disclosure of information related to GMP inspections will not be published as it undermines the purpose of such inspections

12.2. GCP inspections

Disclosure of information related to GCP inspections will not be published as it undermines the purpose of such inspections

12.3. Pharmacovigilance inspections

Disclosure of information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections

12.4. GLP inspections

Disclosure of information related to GLP inspections will not be published as it undermines the purpose of such inspections

13. Innovation Task Force

13.1. Minutes of Innovation Task Force

Action: For information

13.2. Innovation Task Force briefing meetings

Disclosure of information related to briefing meetings taking place with applicants cannot be released at present time as deemed to contain commercially confidential information

13.2.1. ITF Briefing Meeting

Action: For adoption

13.2.2. ITF Briefing Meeting

Action: For adoption

13.2.3. ITF Briefing Meeting

Action: For adoption

13.3. Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004

13.4. Nanomedicines activities

14. Organisational, regulatory and methodological matters

14.1. Mandate and organisation of the CHMP

14.1.1. Discussion of CHMP co-opted member expertise

Action: For discussion

CHMP discussion on the area of expertise of the 5th CHMP co-opted member.

14.1.2. Updated Assessment Report templates

The Assessment Report templates for annual re-assessments and annual renewals have been updated to align them with the newly implemented process for 5 year renewals. Furthermore the specific section "3.5. Special populations: the elderly" has been introduced in the CHMP D80 AR for issues specific to the elderly

Action: For adoption

14.1.3. Draft Scientific Guideline on Post-authorisation efficacy studies (PAES)

Action: For adoption and for 3-months public consultation

Note: It was introduced to CHMP in July 2015 for comments.

The aim of this draft is to provide scientific guidance for MAHs and NCAs on the general need for such studies including within the scope of Delegated Regulation (EU) No 357/2014, on general methodological considerations, on specific situations and on study conduct. Following its adoption by the EMA Scientific Committees the draft guidance will be released for 3-months public consultation in Q4 2015.

14.1.4. Enhanced early dialogue to foster development and facilitate accelerated assessment (PRIME)

Scope: Reflection paper on enhanced early dialogue

Action: For adoption and for 2-months public consultation

14.1.5. Strategic Review and Learning Meetings

Scope: Updated documents on organisational aspects

Action: For information

Principles for organisation of NCA hosted meetings

Responsibilities for confidentiality in NCA Hosted Meetings

14.1.6. Strategic review of the Article 58 procedure

Action: For discussion

14.1.7. Concept paper on guideline on pregnancy and breastfeeding (GVP)

Product- or Population specific considerations III: pregnancy and breastfeeding (EMA/657854/2015)

Action: For adoption

14.2. Coordination with EMA Scientific Committees

14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC)

Summary of recommendations and advice of PRAC meeting held on 05-08 October 2015

Action: For information

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for October 2015

Action: For adoption

14.2.2. Committee for Advanced Therapies (CAT)

CAT draft minutes of meeting held on 15-16 October 2015
Action: For information

14.2.3. Committee for Herbal Medicinal Products (HMPC)

Report from the HMPC meeting held on 28 September -1 October 2015

Action: For information

14.2.4. Paediatric Committee (PDCO)

PIPs reaching D30 at October 2015 PDCO

Action: For information

Report from the PDCO meeting held on7-9 October 2015

Action: For information

14.2.5. Committee for Orphan Medicinal Products (COMP)

Report from the COMP meeting held on 6-8 October 2015
Action: For information

14.2.6. CMDh

Report from the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) on the meeting held on 19-21 October 2015

Action: For information

Question from CMDh to CHMP/PKWP on bioequivalence requirements for generics of amoxicillin and clavulanic acid

Action: For adoption

14.3. Coordination with EMA Working Parties / Working Groups / Drafting Groups

14.3.1. Scientific Advice Working Party (SAWP)

Report from the SAWP meeting held on 5-8 October 2015. Table of conclusions

Action: For information

Scientific advice letters: Disclosure of information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.

14.3.2. Safety Working Party (SWP)

Scope: Election of SWP Chair

Action: For adoption

Scope: Reflection paper on the use of methyl-and propylparaben as excipients in human medicinal products for oral use

Action: For adoption

Scope: Guideline on non-clinical local tolerance testing of medicinal products

Action: For adoption

Scope: Concept paper on a proposal to limit the applicability of the CPMP/CVMP Note for Guidance on Limitations to the Use of Ethylene Oxide in the Manufacture of Medicinal Products to medicinal products for veterinary use

Action: For adoption

SWP final response to HMPC questions on Pulegone

Action: For adoption

Scope: Overview of comments received on Draft guideline on non-clinical local tolerance testing of medicinal products' EMA/CHMP/SWP/2145/2000 Rev. 1

Action: For information

Scope: Overview of comments received on the 'Reflection paper on the use of methyl- and propylparaben as excipients in human medicinal products for oral use' EMA/CHMP/SWP/272921/2012

Action: For information

14.3.3. Quality Working Party (QWP)

Scope: Question and answer on expression/declaration of potency in quantitative and qualitative composition for Vancomycin products

Action: For adoption

Scope: Response to the EDQM request for QWP opinion on new information on alkyl

sulfonates

Action: For adoption

14.3.4. Biologics Working Party (BWP)

Scope: Draft agenda for BWP face-to-face meeting to be held 9-11 November 2015

Action: For information

Scope: Final minutes from face-to-face meeting held 13-15 July 2015

Action: For information

14.3.5. Blood Products Working Party (BPWP)

Scope: Final Minutes of WP meeting held face-to-face-on 28-29 May 2015

Action: For information

14.3.6. Cardiovascular Working Party

Scope: Guideline on clinical investigation of medicinal products for prevention of venous thromboembolism (VTE) in non-surgical patients

Action: for adoption for 6-month public consultation

Scope: Final Minutes of WP meeting held by teleconference on 3 June 2015

Scope: Draft Table of Decisions of WP meeting held by on 30 September 2015

Action: for information

14.3.7. Central Nervous System Working Party (CNSWP)

Scope: Draft Agenda of WP meeting held face-to-face teleconference on 7 October 2015

Scope: Final Minutes of WP meeting held by teleconference on 12 May 2015

Scope: Final Minutes of WP meeting held by teleconference on 12 June 2015

Action: for information

14.3.8. Pharmacokinetics Working Party (PKWP)

Responses to CMDh question to CHMP (PKWP, SWP) regarding potential risk of longer half-life of acitretin

Action: For information

14.3.9. Excipients Drafting Group

Scope: Draft agenda of DG meeting to be held by teleconference on 4 or 5 November 2015

Action: For information

Scope: New mandate of the Excipient drafting group (ExcpDG)

Action: For adoption

Scope: Proposed new core members and Chair

Action: For discussion

14.3.10. Biostatistics Working Party (BSWP)

Scope: Nomination of new observer Barbara Bidzinska (PL)

Action: For adoption

Current membership list

14.3.11. Asthma Guideline Drafting Group

Scope: Guideline on the Clinical Investigation of Medicinal Products for the Treatment of Asthma (CHMP/EWP/2922/01 Rev. 1)

Action: For adoption

14.3.12. CHMP-GCP inspectors working group

Scope: Results of the analysis on the impact of GCP inspection findings on CHMP opinions

Action: For discussion

14.3.13. Joint CVMP/CHMP ad-hoc expert group on the application of the 3Rs (replacement, reduction and refinement) in the regulatory testing of medicinal products (JEG 3Rs)

Scope: EMA representation at EMCDDA Risk Assessment meeting on the new psychoactive substance 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone (α-PVP), 18 November 2015, Lisbon.

Action: For information

14.4. Cooperation within the EU regulatory network

14.4.1. EPAA Annual conference in Brussels (EP), 1st December 2015,

Scope: EMA representation

Action: For information

14.5. Cooperation with International Regulators

14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee

14.6.1. International Society for Stem Cell Research

ISSCR's "Guidelines for Stem Cell Research and Clinical Translation" (EXT/601308/2015)

Action: For adoption

14.7. CHMP work plan

14.8. Planning and reporting

14.9. Others

15. Any other business

15.1. AOB topic

16. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

Oral explanations *(section 2)*

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 3, 4 and 5) or referral procedures (section 10) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

Initial applications *(section 3)*

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 3.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 3.2 (**Day 180 List of outstanding issues**) and 3.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 3.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 3.6, **products in the decision making phase**.

Extension of marketing authorisations according to Annex I of Reg. 1234/2008 *(section 4)*

Extensions of marketing authorisations are applications for the change or addition of new strengths, formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

Type II variations - Extension of indication procedures *(section 5)*

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 4. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

Ancillary medicinal substances in medical devices *(section 6)*

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 *(section 3.5)*

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

Re-examination procedures *(section5.3)*

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

Withdrawal of application *(section 3.7)*

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use) *(section 7)*

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

Pre-submission issues *(section 8)*

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

Post-authorisation issues *(section 9)*

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the

plenary.

Referral procedures *(section 10)*

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found here.

Pharmacovigilance issues *(section 11)*

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

Inspections Issues *(section 12)*

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Innovation task force *(section 13)*

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found here.

Scientific advice working party (SAWP) *(section 14.3.1)*

This section refers to the monthly report from the CHMP's Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found here.

Satellite groups / other committees *(section 14.2)*

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmamacovigilance Risk Assessment Committee (PRAC).

Invented name issues *(section 14.3)*

This section list issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found here.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/